Jupiter Wellness Completes Patient Enrollment in Clinical Study of Novel Cannabidiol Lotion JW-100 for the Treatment of Eczema

Rhea-AI Summary

Jupiter Wellness (NASDAQ:JUPW) has completed enrollment for its clinical study on JW-100, a CBD lotion designed to treat atopic dermatitis (eczema), involving 66 patients. The study is double-blinded and placebo-controlled, with a primary endpoint focused on the Investigator's Static Global Assessment (ISGA) score at 29 days. Final results are expected in Q1 2021. CEO Brian John indicated that if successful, the data will be used for an IND application with the FDA, positioning the company to tap into the $10 billion eczema market.

Positive

• Successful completion of patient enrollment for JW-100 trial
• Potential to file an IND application with the FDA pending positive results
• Access to a lucrative $10 billion eczema market

Negative

• None.

Data Expected Q1 2021 From Study of 66 Patients

JUPITER, FL / ACCESSWIRE / December 22, 2020 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a leading developer of cannabidiol (CBD) based medical therapeutics and wellness products, today announced it has completed patient enrollment in its clinical study to investigate the efficacy and safety of JW-100 its proprietary lotion formulation for the treatment of atopic dermatitis (eczema).

The multi-center, double-blinded, placebo-controlled trial enrolled 66 patients randomized to receive one of three topical formulations including a placebo at least twice per day. The primary endpoint of the study at 29 days is the proportion of success in the Investigator's Static Global Assessment (ISGA) score, a 5-point scale assessment commonly used in clinical trials assessing the severity of atopic dermatitis. Secondary endpoints include the measurement of pain and itch thirty minutes after application. The Company expects to release final data from the study in the first quarter of 2021.

"We are eager to see the results of this trial, and should JW-100 prove effective, we plan to use the data from this study to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration," stated Jupiter CEO Brian John. "With the eczema market valued at more than $10 billion in 2020 and a high percentage of patients unsatisfied with their current treatments, we believe Jupiter will be well-positioned to capitalize on the opportunity with our CBD-based proprietary formulation."

About Jupiter Wellness
Jupiter Wellness, Inc. (NASDAQ:JUPW) is a leading developer of cannabidiol (CBD) based medical therapeutics and wellness products. The Company's clinical pipeline of prescription CBD-enhanced skin care therapeutics address indications including eczema, burns, herpes cold sores, and skin cancer. Jupiter generates revenues from a growing line of proprietary over-the-counter skincare products including its flagship CaniSun™ sunscreen and other wellness brands sold through its robust distribution platform.

For additional information, please visit www.jupiterwellnessinc.com. The Company's public filings can be found at www.Sec.gov.

Safe Harbor Statement
To the extent any statements contained in this presentation of Jupiter Wellness, Inc. (the "Company") contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 and the information that are based upon beliefs of, and information currently available to, the company's management as well as estimates and assumptions made by the company's management. These statements can be identified by the fact that they do not relate strictly to historic or current facts. When used in this presentation the words "estimate," "expect," intend," believe," plan," "anticipate," "projected" and other words or the negative of these terms and similar expressions as they relate to the company or the company's management identify forward-looking statements. Such statements reflect the current view of the company with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the company's industry, its operations and results of operations and any businesses that may be acquired by the company. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, the company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Investor & Public Relations Contact Info
Phone: 561-244-7100
Email: info@jupiterwellnessinc.com

SOURCE: Jupiter Wellness, Inc.

View source version on accesswire.com:
https://www.accesswire.com/621902/Jupiter-Wellness-Completes-Patient-Enrollment-in-Clinical-Study-of-Novel-Cannabidiol-Lotion-JW-100-for-the-Treatment-of-Eczema

FAQ

What is the purpose of the JW-100 clinical study by Jupiter Wellness (JUPW)?

The JW-100 clinical study aims to investigate the efficacy and safety of a CBD lotion for treating atopic dermatitis.

How many patients were enrolled in the JW-100 study for eczema?

A total of 66 patients were enrolled in the JW-100 study.

When can we expect results from the JW-100 clinical trial?

Final data from the JW-100 study is expected to be released in the first quarter of 2021.

What regulatory step will Jupiter Wellness take if JW-100 proves effective?

If JW-100 shows positive results, Jupiter Wellness plans to file an Investigational New Drug (IND) application with the FDA.

What is the estimated value of the eczema market mentioned in the press release?

The eczema market is valued at more than $10 billion.